3-(1-methyl-1H-imidazol-2-yl)propanonitrile | 133485-23-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(1-methyl-1H-imidazol-2-yl)propanonitrile
• 英文别名: 1-methyl-2-1H-imidazolepropanamine；3-(1-methyl-1H-imidazol-2-yl)propan-1-amine；1H-Imidazole-2-propanamine, 1-methyl-；3-(1-methylimidazol-2-yl)propan-1-amine
• CAS: 133485-23-1
• 化学式: C₇H₁₃N₃
• mdl: MFCD19103323
• 分子量: 139.2
• InChiKey: RBLFLGWPHLVQCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-cyano-S-methyl-N'-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]isothiourea 、 3-(1-methyl-1H-imidazol-2-yl)propanonitrile 以 吡啶 为溶剂， 以38%的产率得到
  参考文献：
  名称：

  Buschauer; Postius; Szelenyi, Arzneimittel-Forschung/Drug Research, 1985, vol. 35, # 7, p. 1025 - 1029

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(1-methyl-1H-imidazol-2-yl)propanonitrile 在 镍 ammonium hydroxide 、 氢气 作用下， 反应 6.0h， 以86%的产率得到3-(1-methyl-1H-imidazol-2-yl)propanonitrile
  参考文献：
  名称：

  的合成ñ - [3-（1-甲基-1- ħ -2-咪唑基）丙基]苯甲酰胺和ñ - [3-（1-甲基-1- ħ -2-咪唑基）丙基]苯磺酰胺

  摘要：

  一系列取代的N-（4-取代的苯甲酰基）-N- [3-（1-甲基-1 H-咪唑-2-基）丙基]胺（13）和N-芳基磺酰基-N- [3-（ 1-甲基- 1 H ^ -咪唑-2-基）丙基]胺（14）从3-（1-甲基- 1的反应制得ħ咪唑-2-基）丙-1-胺（7）用分别是取代的苯甲酰氯或取代的苯磺酰氯。化合物7通过两种独立的方法制备。

  DOI：

  10.1002/jhet.5570420542

文献信息

• [EN] NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES<br/>[FR] NOUVEAUX COMPOSÉS COMME STIMULANTS RESPIRATOIRES POUR LE TRAITEMENT DE TROUBLES OU DE MALADIES DE CONTRÔLE DE LA RESPIRATION
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2012074999A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明涵盖了用于治疗患有呼吸控制疾病或紊乱的受试者的组合物。本发明还包括一种治疗患有呼吸系统疾病或紊乱的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。本发明还包括一种预防或稳定患有呼吸节律不稳定的受试者的方法，包括向受试者施用本发明的药物配方的治疗有效量。
• [EN] QUINOXALINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS À BASE DE QUINOXALINE ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2015161142A1

  公开（公告）日：2015-10-22

  This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.

  这项发明提供了公式I及其子集的化合物：其中T、J、R、R4、Rq、o、RA和RB以及其子集如规范中所述。这些化合物是NAMPT的抑制剂，因此可用于治疗癌症、炎症性疾病或T细胞介导的自身免疫疾病。
• Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
  申请人：Mannion James C.

  公开号：US20120295911A1

  公开（公告）日：2012-11-22

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明包括用于治疗需要呼吸控制疾病或障碍的受体的组合物。本发明还包括一种治疗需要呼吸系统疾病或障碍的受体的方法，包括向受体施用本发明的药物制剂的治疗有效量。本发明还包括一种预防或稳定需要呼吸节律的受体的方法，包括向受体施用本发明的药物制剂的治疗有效量。
• Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases
  申请人：Dax Scott L.

  公开号：US20120142647A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

  本发明包括用于治疗呼吸控制疾病或障碍的组合物，适用于需要该治疗的受试者。本发明还包括一种治疗呼吸系统疾病或障碍的方法，包括向受试者投予本发明的药物制剂的治疗有效量。本发明还包括一种预防或稳定受试者呼吸节律不稳定的方法，包括向受试者投予本发明的药物制剂的治疗有效量。
• NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES
  申请人：GALLEON PHARMACEUTICALS, INC.

  公开号：US20140371224A1

  公开（公告）日：2014-12-18

  The present invention includes compounds, and compositions comprising the same, that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.

  本发明包括化合物及其组合物，适用于治疗需要治疗呼吸控制疾病或障碍的患者。本发明还包括一种治疗需要治疗呼吸系统疾病或障碍的患者的方法，包括向患者施用本发明中化合物的治疗有效量。本发明还包括一种预防或稳定需要稳定呼吸节律的患者的方法，包括向患者施用本发明中化合物的治疗有效量。